Navigation Links
First Bedside DNA Test to be Distributed by Chirus in UK
Date:12/27/2012

Ottawa, Ontario (PRWEB) December 27, 2012

Spartan Bioscience today announced a distribution agreement with Chirus for the Spartan RX—the first point-of-care DNA test in medicine.(1) Chirus specializes in point-of-care diagnostic products in the UK.

The Spartan RX point-of-care DNA testing system identifies carriers of CYP2C19 loss-of-function mutations, which are carried by approximately 30% of the world’s population.(2) Genetic carriers who receive Plavix® (clopidogrel) following a cardiac stent have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(3) In 2009, Plavix® was the second best-selling drug in the world, with over $9 billion in revenues.

“Spartan is very excited to extend its distribution network to the UK,” said Paul Lem, M.D., CEO of Spartan Bioscience. “We have chosen Chirus as our partner based on their market development expertise and existing customer base.”

“The Spartan RX system is a breakthrough towards bringing rapid genomic testing to the point of care,” said Talat Syed, Director of Chirus. “For the first time, cardiologists can genotype patients in the cardiac catheterization suite.”

About the Spartan RX CYP2C19
The Spartan RX CYP2C19 is the first point-of-care DNA test in medicine.(1) It identifies carriers of CYP2C19 genetic mutations in 1 hour. These mutations are carried by approximately 30 percent of the world’s population.(2) Genetic carriers who receive Plavix® following a cardiac stent insertion to open clogged arteries have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(3) Currently, genetic testing is performed in central labs and it takes up to seven days to get a test result back. A rapid test is needed because most of the complications for CYP2C19 carriers occur in the first 24 to 48 hours.(3,4) In March 2010, the FDA issued a warning for Plavix regarding CYP2C19 poor metabolizers. The Spartan RX CYP2C19 has CE IVD Mark regulatory approval for Europe and other countries recognizing the CE IVD Mark. Spartan Bioscience is working towards FDA 510(k) clearance in the United States. For more information, please visit our website at: http://www.spartanbio.com/products/spartan-rx

About Spartan Bioscience
Spartan Bioscience is the leader in point-of-care DNA testing. The Spartan RX is the first complete sample-to-result, point-of-care DNA testing system in medicine. It is a fully integrated DNA collection, extraction and analysis platform, with an intuitive interface that is easy to operate—no laboratory training required. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.

The Spartan logo is a registered trademark of Spartan Bioscience Inc.
Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals.

1. Roberts JD et al. (2012). Lancet. 379: 1705–1711.
2. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–111.
3. Mega JL et al. (2009). N Engl J Med. 360:354–362.
4. Wiviott SD et al. (2007). N Engl J Med. 357:2001–2015.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10231792.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
5. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
8. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
9. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
10. Amgen Announces 2012 First Quarter Dividend
11. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... a new agreement with Singapore-based Global Stem Cells Network (GSCN) and its affiliate ... and Singapore in the latest adipose and bone marrow therapies. , Through ...
(Date:2/9/2016)... , ... February 08, 2016 , ... ... , Location: Baruch S. Blumberg Institute at the Pennsylvania Biotechnology Center of Bucks ... Institute and The Commonwealth Medical College (TCMC) will hold an open house for ...
(Date:2/9/2016)... ... 09, 2016 , ... The publishing industry has been witnessing ... one of the popular publication models that has received wider acknowledgement from the ... International Conferences across the globe, OMICS International is all set to ...
(Date:2/9/2016)... Massachusetts , February 9, 2016 ... Enables Children to Take Part in Life-Changing Camp ... a new initiative designed to positively affect the lives of children ... disease care. --> SHPG ) is announcing a new ... rare diseases, as well as the future of rare disease care. ...
Breaking Biology Technology:
(Date:1/28/2016)... 28, 2016 Synaptics (NASDAQ: SYNA ), a leading ... second quarter ended December 31, 2015. --> ... fiscal 2016 increased 2 percent compared to the comparable quarter last ... fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... for the first quarter of fiscal 2016 grew 9 percent over ...
(Date:1/25/2016)...   Unisys Corporation (NYSE: UIS ) today announced ... International Airport, New York City , to help ... to enter the United States using passports ... pilot testing of the system at Dulles last year. The ... during January 2016. --> pilot testing of the ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
Breaking Biology News(10 mins):